Christopher R. Heery
Net Worth

Last updated: 19 Dec 2019

What is Christopher R. Heery net worth?

The estimated net worth of Dr. Christopher R. Heery is at least $3,525,480 as of 19 Dec 2019. He owns shares worth $1,200 as insider and has received compensation worth at least $3,524,280 in Precision BioSciences, Inc..

What is the salary of Christopher R. Heery?

Dr. Christopher R. Heery salary is $587,380 per year as Consultant in Precision BioSciences, Inc..

How old is Christopher R. Heery?

Dr. Christopher R. Heery is 45 years old, born in 1980.

What stocks does Christopher R. Heery currently own?

As insider, Dr. Christopher R. Heery owns shares in one company:

Company	Title	Shares	Price per share	Total value
Precision BioSciences, Inc. (DTIL)	Consultant	250	$4.8	$1,200

What does Precision BioSciences, Inc. do?

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.